ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Chemical modifications allow single-stranded RNAs to silence gene expression via the RNA interference (RNAi) pathway, scientists at Isis Pharmaceuticals, in Carlsbad, Calif., report (Cell, DOI: 10.1016/j.cell.2012.08.014). Conventional small interfering RNAs (siRNAs) are double-stranded and require formulation with lipids for efficient delivery to tissues. Single-stranded RNAs don’t need such lipid formulations, but they have difficulty entering the RNAi pathway. Walt F. Lima, Stanley T. Crooke, and coworkers chemically modified single-stranded RNA so that it interacts directly with Ago2, the enzyme that is responsible for mRNA cleavage in RNAi. Key modifications to the single-stranded siRNA include a 5´-(E)-vinylphosphonate (shown), phosphorothioate linkages between nucleotides, and a mixture of 2´-fluoro, 2´-methoxy, and 2´-methoxyethyl ribonucleotides. The vinylphosphonate, which is conformationally and stereoelectronically similar to natural 5´-phosphates, is necessary for direct loading into Ago2. David R. Corey of the University of Texas Southwestern Medical Center, in Dallas, and coworkers collaborated with the Isis team to use single-stranded siRNAs to inhibit expression of mutant huntingtin protein, which causes Huntington’s disease (Cell, DOI: 10.1016/j.cell.2012.08.002).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter